Compare Quest Diagnostics Inc (DGX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.74. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| DGX | YINN | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.02 | $56.62 |
52-Week Low | $166.42 | $21.45 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
YINN, the Direxion Daily FTSE China Bull 3x ETF, trades at $25.25, down 0.43% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral and RSI_6 suggests overbought conditions. Recent sentiment has improved with a Seeking Alpha rating upgrade from bearish to neutral, citing China's relative undervaluation and improved macro backdrop, though concerns remain about the fund's leveraged structure and value trap risks in Chinese equities.
The outlook for YINN is cautiously optimistic, driven by China's tech sector momentum and substantial government AI investment plans. However, significant risks include geopolitical tensions with the U.S., the fund's 3x leverage amplifying volatility, and ongoing regulatory uncertainties. Investors should weigh China's economic stimulus against structural challenges in the market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
